Apertura Gene Therapy Launches with $67M

Posted by ISPE Boston
On May 5, 2022

Apertura Gene Therapy has launched with a Series A financing of up to $67M from Deerfield Management Company to develop genetic medicines. Deerfield Management has also committed additional operational support. Apertura is based at the Cure, Deerfield’s innovation campus in New York City. Apertura is founded on a pair of platform technologies developed in the […]

First ISPE Boston Podcast Club a Success!

Posted by Jesse McLaughlin
On May 3, 2022

Last Wednesday we had our very first “Podcast Club” meeting. No, we didn’t just sit around with our earbuds in listening to our favorite podcasts…and I don’t think anyone was wearing a t-shirt of their favorite podcast host… We did, however, have a great discussion about the future of the Pharma industry! Kind of like […]

Chapter Member Anniversaries: May 2022

Posted by ISPE Boston
On May 3, 2022

Please congratulate the following members celebrating milestone anniversaries in May 2022. Their dedication to ISPE, the Boston Area Chapter and the industry is applauded! Over Twenty Years Beth Ann Billotto, Regeneron Pharmaceuticals Inc Karen Conte, Pfizer Timothy Crowley, Sentrol, Inc. John Evers, Lantheus Medical Imaging Joshua Froimson, AbbVie Bioresearch Center Doyle Johnson Jr., IPS Marina […]

Welcome New Members April 2022!

Posted by ISPE Boston
On May 3, 2022

We would like to introduce the Members who joined ISPE in April 2022, welcome them to the Chapter and encourage them (and all our members) to take advantage of the many professional development, networking and information resources available through ISPE. Fellow ISPE members are a terrific resource for help with everyday professional challenges. And the […]

Checkmate Pharmaceuticals Acquired by Regeneron

Posted by ISPE Boston
On April 28, 2022

Cambridge-based Checkmate Pharmaceuticals has agreed to be acquired by Regeneron in a transaction that values Checkmate at approximately $250 million. Checkmate is a clinical stage biopharm focused on harnessing the power of the immune system to combat cancer. The transaction is expected to close in mid-2022. Checkmate’s lead investigational candidate is vidutolimod which is administered […]

Announcing the Massachusetts Life Sciences Workforce Conference on June 8

Posted by ISPE Boston
On April 28, 2022

Life Sciences Workforce Conference June 8th, 2022, 8:30am-3:30pm, Framingham State University (Free Online Live Stream Available) The 7th Annual Massachusetts Life Sciences Workforce Conference on June 8th 8:30am-3:30pm at Framingham State University will welcome influential leaders from Boston Medical Center, Vertex, Mass Bio, Blueprint Medicines, Northeastern University, Suffolk University, and special guest, Secretary of Labor […]

Reify Health Raises $220 Million to Improve Diversity in Clinical Trials

Posted by ISPE Boston
On April 28, 2022

Reify Health has raised $220 million in a Series D funding round. The funding round, which brings the company’s valuation to over $4.8 billion, was secured to accelerate the company’s efforts to improve diversity and representation in clinical trial participation. Certain minority communities have been heavily underrepresented in clinical trials, which presents a significant health […]

Symeres acquires Woburn’s Organix, Adds Strategic Foothold in US

Posted by ISPE Boston
On April 28, 2022

Leading European drug discovery CRO/CDMO Symeres is set to acquire Woburn-based Organix, a provider of high-quality organic chemistry services focused on lipids. The Organix acquisition adds a high-quality presence in the US market, where Symeres generates nearly 50% of its revenues, and broadens Symeres’ drug discovery offering into the fast-growing lipids market, addressing mRNA therapeutics […]

bluebird bio Restructures to Cut Costs

Posted by ISPE Boston
On April 15, 2022

Following a review of its strategic priorities, bluebird bio is initiating a comprehensive restructuring intended to deliver up to $160 million in cost savings over the next two years. bluebird intends to sharpen its focus on near-term catalysts, including anticipated FDA approvals for its gene therapies for beta-thalassemia and cerebral adrenoleukodystrophy in 2022, and the potential submission of […]

LifeMine Raises $175 Million, Partners with GSK

Posted by ISPE Boston
On April 15, 2022

Cambridge-based LifeMine Therapeutics has raised $175 million in a Series C financing to advance the company’s proprietary, evolutionarily-derived genomic drug discovery platform, Avatar-Rx. The platform searches the fungal biosphere for novel GEMs (genetically-encoded small molecules) having a predetermined target and biological function. Downstream of GEM discovery, Avatar-Rx advances new product candidates rapidly through preclinical discovery […]

Page 36 of 118«‹34 353637 38 ›»